2X1:ETR
Abivax SA
€ 83.55
arrow_downward
-0.71%(-0.60) 1D
10-р сарын 2, 17:35:35 (GMT+2) · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 2X1...
Open
€ 83.15
High
€ 84.50
Low
€ 83.00
Mkt. cap
7.20 тэрбум
Avg. vol.
1.78 мян
Volume
842.00
52-wk high
€ 137.40
52-wk low
€ 60.85
EPS
-€ 5.20
No. of employees
98
Open
€ 83.15
High
€ 84.50
Low
€ 83.00
Mkt. cap
7.20 тэрбум
Avg. vol.
1.78 мян
Volume
842.00
52-wk high
€ 137.40
52-wk low
€ 60.85
EPS
-€ 5.20
No. of employees
98
News stories
From web sources and news partners
MarketBeat
·
1 өдрийн өмнө
Abivax (NASDAQ:ABVX) Stock Price Down 5.1% - Should You Sell?
TipRanks
·
2 өдрийн өмнө
Abivax to Showcase Extensive Obefazimod Data at UEG Week 2026
Stock Titan
·
2 өдрийн өмнө
Researchers will present three-year data on a drug for ulcerative colitis
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded2013 оны 12-р сарын 4
Headquarters-
Sector-
Websiteabivax.com